Patents by Inventor Stephan A. BILLSTEIN

Stephan A. BILLSTEIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT AND PREVENTION OF BACTERIAL SKIN INFECTIONS USING ORITAVANCIN
    Publication number: 20160101148
    Abstract: Methods for the treatment and prevention of bacterial skin infections using the glycopeptide antibiotic oritavancin are disclosed.
    Type: Application
    Filed: April 15, 2014
    Publication date: April 14, 2016
    Applicant: THE MEDICINES COMPANY
    Inventors: Greg MOECK, Theresa MATKOVITS, Stephan A. BILLSTEIN, Gina EAGLE, Ketna PATEL, Francis F. ARHIN
  • Penciclovir or Famciclovir for Treatment of Recurrent Genital Herpes with a One-Day Application
    Publication number: 20110257204
    Abstract: A method for the treatment of recurrent genital herpes, in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of penciclovir or famciclovir, or a pharmaceutically acceptable salt thereof for a treatment period of one day.
    Type: Application
    Filed: February 16, 2011
    Publication date: October 20, 2011
    Inventors: Stephan BILLSTEIN, Estate of Stephen Sacks, Marika Sacks
  • Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
    Publication number: 20080090878
    Abstract: The present invention relates to a combination of a first agent including either a 5-HT4 receptor agonist or antagonist or a 5-HT3 receptor antagonist and a co-agent and pharmaceutical compositions and formulations containing the combination. The present invention also relates to a method of treating a gastrointestinal and abdominal viscera disorder by administering the pharmaceutical compositions to a patient. The pharmaceutical compositions may also be employed as laxatives, to prepare a patient for colonoscopy and to regulate and stabilize enterochromaffin cell secretory, pain and motility mechanisms, afferent fiber activity and GI and lower abdominal smooth muscle cells. The dosage is preferably oral and administration is preferably once or twice a day. The preferred first agent is tegaserod.
    Type: Application
    Filed: October 9, 2007
    Publication date: April 17, 2008
    Inventors: Stephan Billstein, Peter Dumovic, Nicola Franco, Mark Iwicki, Hans-Juergen Pfannkuche, Edward Wilusz